In parallel, B7-H3-directed CAR-T cells incorporating single-chain variable fragments (scFvs) against B7-H3 have shown superior efficacy over monoclonal antibodies in both solid and hematologic tumors (Guo et al., 2025), further underscoring its importance in personalized cancer therapy. The gene discussed is CD276; the disease is cancer.